Elad Sharon and Colleagues: How a Common Trait Unfairly Excludes Black Patients from Cancer Trials
Elad Sharon, Associated Professor of Medicine at Dana-Farber, shared a post on X:
“Very proud of this effort led by one of our former Dana-Farber fellows, Lauren Merz, on the Duffy null phenotype. Thanks to JAMA Oncology for highlighting! Important to see that many otherwise healthy patients are unfairly being excluded because of an arbitrary number… the National Cancer Institute”
Quoting JAMA Oncology’s post:
“Absolute neutrophil count–based eligibility criteria in cancer trials disproportionately exclude Black patients with the Duffy null phenotype, suggesting the need for Duffy status–specific thresholds to improve trial equity.”
Title: Duffy Null–Associated Absolute Neutrophil Counts and Cancer Clinical Trial Eligibility
Authors: Lauren E. Merz, Yating Wang, Angel Cronin, Elad Sharon, Thomas P. Walsh, Stephen P. Hibbs, Christopher S. Lathan, Andrew Hantel
Read full article here.
Never miss hematology updates with Hemostasis Today.
-
Aug 22, 2026, 15:13Arthur Allen: Empowering Clinicians to Act
-
Aug 22, 2026, 15:11Bassem M. Mohammed: Factor VIII Structure Analysis Makes the Cover of the Journal of Thrombosis and Haemostasis
-
Aug 22, 2026, 15:03Ahmed Reda: Your Red Blood Cell Can Tell a Story – Not All Anemia Looks the Same
-
Aug 22, 2026, 14:50Marco Meloni: Clinical Management of the Diabetic Foot Attack
-
Aug 22, 2026, 14:41Nico Gagelmann: What is the Future for Patients with Myeloproliferative Neoplasms?
-
Aug 22, 2026, 14:36Arun V J: Leadership Is a Practice, Not a Position – TRAM Masterclass with Judith Chapman
-
Aug 22, 2026, 13:38Jerome Hadjadj: A New Approach to Refractory Immune Thrombocytopenia
-
Aug 22, 2026, 13:25Christopher Robinson: Hematologic Response to Iron Therapy and Stillbirth Risk
-
Aug 22, 2026, 13:24Philippa Hill: Blood Clot Awareness – Recognize the Signs, Prevent the Risk